Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hasegawa, Kosei
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer	Active, not recruiting	3	502	Europe, Canada, Japan, US, RoW	tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed	Seagen Inc., Genmab	Cervical Cancer	07/23	08/25
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line	Recruiting	3	260	Europe, Canada, Japan, RoW	Carboplatin-Paclitaxel, Dostarlimab	ARCAGY/ GINECO GROUP, GlaxoSmithKline	Endometrial Cancer	04/26	10/29
GOTIC-025, NCT04641728: Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer	Active, not recruiting	2	28	Japan	Pembrolizumab, KEYTRUDA, Olaparib, LYNPARZA	Saitama Medical University International Medical Center, Tokyo University, National Cancer Center, Japan, Cancer Institute Hospital, Japan, Aichi Cancer Center	Cervical Cancer	12/22	12/23
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer	Recruiting	2	390	Europe, Japan, RoW	Chemotherapy, Bevacizumab-Awwb, Niraparib	ARCAGY/ GINECO GROUP, GSK	Ovarian Cancer	02/27	02/30
RUBY-J, NCT06317311: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer	Recruiting	2	36	Japan	Dostarlimab, Carboplatin, Paclitaxel	GlaxoSmithKline	Carcinoma	07/26	08/27
SaINT-ov02, NCT05158062: Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer	Recruiting	2	35	Japan	pembrolizumab, KEYTRUDA, olaparib, LYNPARZA, bevacizumab, AVASTIN, carboplatin, paclitaxel, docetaxel	Kosei Hasegawa, MD, PhD	Carcinoma, Ovarian Epithelial	11/24	11/24
NCT06555744: A Study of ZW191 in Participants With Solid Tumors	Recruiting	1	145	Japan, US, RoW	ZW191	Zymeworks BC Inc.	Advanced Solid Tumors	12/26	01/27